Activist investors hold stake in Elliott Glaxo

Billionaire conspiracy in Glaxosmithkline

  • Notorious activist investor Elliott Management has acquired a multi-billion pound stake in GlaxoSmithline
  • Elliott, run by US billionaire Paul Singer, has earned a ‘significant’ position in the underperforming company.
  • Citi surprised as the shares raided at 1348.4p, up 4.6 percent or 58.8p.

Notorious activist investor Elliott Management has snapped up a multi-billion pound stake in Glaxosmithkline as it prepares to shake up the FTSE100 drug maker.

Elliott, run by US billionaire Paul Singer, has accumulated a ‘significant’ position in the underperforming company in a move that could set the stage for a blockbuster boardroom fight.

Citi made a surprise move as shares raced at 1348.4p, jumping 4.6 percent or 58.8p.

Conflict: GSK’s boss and one of the most powerful women in the British business, Emma Emma Walsley, is trying to raise the fortune of the company’s flag

But Elliott’s sudden appearance on GSK’s shareholder register is understood to have alerted higher officials, who are drafting heavyweight advisors in an attempt to reduce the company’s defenses.

Dame Emma Walmsley, the boss of GSK and one of the most powerful women in the British business, is trying to raise the company’s flag by separating its consumer products from its pharma and vaccine division. But shareholders have begun to develop uneasiness – especially since Walmsley, which has backgrounds in L’Oreal and Diageo Consumer Goods, announced its intention to lead the more prestigious pharma division after the split.

City sources suggested that there would be ‘significant concerns’ among some shareholders if insisted on taking the role of 51-year-old Walmsley (picture correct).

Since he took over as chief executive of GSK in 2017, the shares have fallen 22 percent, and although shareholders were largely satisfied with his initial progress, rivals Pfizer and AstraZeneca have fared better. Both have released Kovid’s vaccines – though Astra boss Pascal Soriot has criticized Australia for staying in their family home as blood clots come into question – while GSK’s efforts to collaborate with Sanofi and Curevac Despite it has not arrived yet.

The turbulence at GSK could be beneficial for Elliott, as it tries to create factions among the company’s investor base and pull more shareholders around the way of thinking.

After its separation, GSK was planning to run its two main divisions as separate companies. Pfizer is already around a third of the consumer, with products ranging from sensodine toothpaste to nicorate patches. But a Citi source speculated that Elliott might try to establish sales of its pharmaceuticals division, which ranges from HIV treatment to cutting-edge cancer drugs, to a bigger competitor than to keep it as a standalone company.

Elliott has made another coup in the pharmaceutical sector only. It invested in American firm Alexion Pharmaceuticals in late 2017 and initially insisted on improving the company’s performance from behind closed doors.

But last year, it publicly told Alexian to sell itself, with management efforts to buy smaller rivals going nowhere.

Within seven months, Elliott had sold Alexison to Astrigeneca of Britain for £ 30 billion.

A Citi investor told the Mail that Elliott was ‘insisting on an open door’ with GSK, as the separation of pharma and consumer was already underway.

But some shareholders are increasingly supporting Walmsley, pointing out that the job they inherited was never going to be easy.

GSK and Elliott declined to comment.

What is ELLIOTT?

Activist investor Elliott Management is famous for sparking some of the fiercest corporate wars of the past decade.

The firm has a quiet private equity branch, known in the UK as the owner of the book shop chain Waterstone.

But its bread-and-butter is snapping up firms that are ripe for change, and then agitate for noise. It will often maintain relationships with many potential buyers, such as private equity firms or major corporates, who Elliott has completed his work with and can buy the company.

In theory, this allows Elliott to make a profit on the shares he buys, which he then distributes to his investors and owners.


Back to top button